Linc01234 promotes cell proliferation and metastasis in oral squamous cell carcinoma via miR-433/PAK4 axis

Liu, Deyu; Jian, Xie; Xu, Ping; Zhu, Rong; Wang, Yuan

doi:10.1186/s12885-020-6541-0

Cited by 27 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same as BANCR, Yang et al reported that the average OS of OSCC patients with low CASC9 expression was longer than those with high CASC9 expression by Kaplan-analysis, and COX regression analysis also revealed that the CASC9 expression level was an independent predictor of the OSCC prognosis [ 29 ]. In addition, similar reports of other lncRNAs such as LINC01234 [ 73 , 74 ], colon cancer–associated transcript 2 (CCAT2) [ 87 ], FOXD2-AS1 [ 44 ] and FTH1P3 [ 45 ] were also confirmed to be unregulated in OSCC tissues and associated with low OS, which indicated the poor prognostic capability.…”

Section: Translational Potential Of Lncrnas In Osccmentioning

confidence: 61%

Long Non-Coding RNA (lncRNA) in Oral Squamous Cell Carcinoma: Biological Function and Clinical Application

Tang

Fang

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is a type of malignancy with high mortality, leading to poor prognosis worldwide. However, the molecular mechanisms underlying OSCC carcinogenesis have not been fully understood. Recently, the discovery and characterization of long non-coding RNAs (lncRNAs) have revealed their regulatory importance in OSCC. Abnormal expression of lncRNAs has been broadly implicated in the initiation and progress of tumors. In this review, we summarize the functions and molecular mechanisms regarding these lncRNAs in OSCC. In addition, we highlight the crosstalk between lncRNA and tumor microenvironment (TME), and discuss the potential applications of lncRNAs as diagnostic and prognostic tools and therapeutic targets in OSCC. Notably, we also discuss lncRNA-targeted therapeutic techniques including CRISPR-Cas9 as well as immune checkpoint therapies to target lncRNA and the PD-1/PD-L1 axis. Therefore, this review presents the future perspectives of lncRNAs in OSCC therapy, but more research is needed to allow the applications of these findings to the clinic.

show abstract

Section: Translational Potential Of Lncrnas In Osccmentioning

confidence: 61%

Long Non-Coding RNA (lncRNA) in Oral Squamous Cell Carcinoma: Biological Function and Clinical Application

Tang

Fang

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…miRNAs are small endogenous RNA molecules which post-transcriptionally silence gene expression in both biological and pathogenic contexts. Previous studies demonstrated that miR-433 was low expressed and exerted anti-tumor effects in different neoplasms [30]. Moreover, miR-433-3p suppressed hematopoietic cell growth and differentiation in myeloproliferative neoplasms, while promoted osteoblast differentiation during bone formation, suggesting the roles of miR-433-3p on tumor development and cell differentiation [31,32].…”

Section: Discussionmentioning

confidence: 96%

LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis

et al. 2020

View full text Add to dashboard Cite

Objective: ER+ breast cancer is the most common type of breast cancer, which seriously affects the physical and mental health of women. Recently, lncRNAs mediated tumor-associated macrophages (TAM) were identified to involve in tumorigenesis. Therefore, the present study aimed at demonstrating the regulatory network of GNAS-AS1 in TAM-mediated ER+ breast cancer progress. Methods: The expression levels of genes were evaluated using qRT-PCR. The proportions of polarized macrophages (M1, M2) were assessed by flow cytometry. Cell proliferation, migration and invasion were evaluated by CCK-8, wound healing and transwell assay, respectively. Double-luciferase reporter system was used to detect the interaction between molecules. Western blot was applied to test protein levels. Results: The expression of GNAS-AS1 was obviously increased in ER+ breast cancer tissues and cell lines, as well as M2 macrophages. GNAS-AS1 facilitated the capabilities of proliferation, migration and invasion of ER+ breast cancer cells by accelerating M2 macrophage polarization via directly sponging miR-433-3p. GATA3, as a target of miR-433-3p, could positively regulate by GNAS-AS1. Furthermore, either miR-433-3p overexpression or GATA3 knockdown impaired the effects of GNAS-AS1 on M2 macrophage polarization and ER+ breast cancer cells progression. Conclusion: GNAS-AS1/miR-433-3p/GATA3 axis promoted proliferation, metastasis of ER+ breast cancer cells by accelerating M2 macrophage polarization. The mechanism may provide a new strategy and target for ER+ breast cancer treatment.

show abstract

“…LINC01234 is upregulated in colorectal cancer, gastric cancer, and oral cancer and high expression correlates with poor prognosis. It is related to tumor stage and lymph node metastasis, and promotes cancer cell proliferation, metastasis, and inhibits apoptosis [ 58 – 60 ]. BACE1-AS is significantly overexpressed in liver cancer, has a tumorigenic effect, and predicts poor overall survival and recurrence-free survival[ 61 ].…”

Section: Discussionmentioning

confidence: 99%

N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer

Nie

Tan

2022

Hereditas

View full text Add to dashboard Cite

Background With a lack of specific symptoms, ovarian cancer (OV) is often diagnosed at an advanced stage. This coupled with inadequate prognostic indicators and treatments with limited therapeutic effect make OV the deadliest type of gynecological tumor. Recent research indicates that N6-methyladenosine (m6A) and long-chain non-coding RNA (lncRNA) play important roles in the prognosis of OV and the efficacy of immunotherapy. Results Using the Cancer Genome Atlas (TCGA) OV-related data set and the expression profiles of 21 m6A-related genes, we identified two m6A subtypes, and the differentially expressed genes between the two. Based on the differentially expressed lncRNAs in the two m6A subtypes and the lncRNAs co-expressed with the 21 m6A-related genes, single-factor cox and LASSO regression were used to further isolate the 13 major lncRNAs. Finally, multi-factor cox regression was used to construct a m6A-related lncRNA risk score model for OV, with good performance in patient prognosis. Using risk score, OV tumor samples are divided into with high- and low-score groups. We explored the differences in clinical characteristics, tumor mutational burden, and tumor immune cell infiltration between the two groups, and evaluated the risk score’s ability to predict the benefit of immunotherapy. Conclusion Our m6A-based lncRNA risk model could be used to predict the prognosis and immunotherapy response of future OV patients.

show abstract

Linc01234 promotes cell proliferation and metastasis in oral squamous cell carcinoma via miR-433/PAK4 axis

Cited by 27 publications

References 34 publications

Long Non-Coding RNA (lncRNA) in Oral Squamous Cell Carcinoma: Biological Function and Clinical Application

Long Non-Coding RNA (lncRNA) in Oral Squamous Cell Carcinoma: Biological Function and Clinical Application

LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis

N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer

Contact Info

Product

Resources

About